ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / SPTX / earnings
CTY (50) HROW (53) JANX (37) MLTX (32) ⌘ Pro Terminal →

Seaport Therapeutics Inc. (SPTX) Next Earnings Date & Expected ±12.5% Move

$20.01 +2.09% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $20.05

Seaport Therapeutics Inc. (SPTX) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $1.05B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SPTX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SPTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Seaport Therapeutics Inc. (NASDAQ: SPTX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $20.01 (+2.09% 1D, market cap $1.05B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, SPTX ranks #287 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SPTX compare to CTY and HROW in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SPTX carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CTY (City Therapeutics Inc.) holds a D grade (50/100 RQD, P/E N/A, ROIC —, cap $1.04B) and HROW (Harrow Inc.) posts a D+ grade (53/100 RQD, P/E N/A, ROIC 42.9%, cap $1.06B). Among the 5-stock peer group, SPTX leads on earnings multiple (N/A) while HROW leads on capital efficiency (42.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SPTX?
▼

Per SPTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002042347), Seaport Therapeutics Inc. generated $104.6M in revenue, $0 in net income, and $0 in free cash flow against $249.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $20.05 (+0.19%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 28.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510048
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Cash (10)Whales (7)SEC (13)Macro (9)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-4.5% Base Target
$30 Bull$19 Base$15 Bear
📬 FREE SPTX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SPTX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (48/100 Composite)
🔍 WHY SPTX SCORES 48/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 28.1% FCF Margin ($29.4M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning7/20 pts (-13 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-13 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
40
Grade D$16.08+19.9% Next Q
Q2 (-2Q)
43
Grade D$19.28+10.4% Next Q
Q3 (-1Q)
45
Grade D$21.28-6% Next Q
Current
48
Grade D$20.01-5.6% Hist 90D α
Trajectory: D (40) → D (48)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SPTX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SPTX currently carries a cautious 48/100 (D) rating due to Whale & Options Positioning (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($21.01) and Max Pain ($21.01) forces dealer call-delta covering toward $29.80.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SPTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SPTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 48%NO 52%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~56 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$2.50 Expected Swing
$17.51 (-12.5%)Spot $20.01$22.51 (+12.5%)
MODEL EARNINGS SETUP GAUGE

SPTX Quantitative Pre-Earnings Setup: 48/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (48/100)Model Risk Weight (52/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$104.6M$0$052%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SPTX)

  • ✓Walkthrough of SPTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
SPTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +17.71%📐 HORIZONTAL RANGE
2026-11-03O $21.10H $21.10L $19.60C $20.01VOL 549.2K
RES: $31.84SUP: $15.36SMA50: $21.01SMA200: $20.13
$29.33$25.40$21.48$17.56$13.63RES $31.84SUP $15.36$20.012026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SPTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SPTX Butterfly Map → + Track SPTX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SPTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SPTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SPTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SPTX)

Health Care Rank #287 of 1015 ⚔️ CTY vs SPTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SPTX vs. CTY, HROW, JANX, MLTX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Seaport Therapeutics Inc. (SPTX) ranks #287 by composite RQD confidence (48/100, grade D) and #352 by equity capitalization ($1.05B). Within this direct 5-issuer industry benchmark cohort, SPTX leads on earnings valuation at N/A trailing P/E, while HROW leads on capital efficiency and profitability with 42.9% ROIC and 75.1% gross margin. HROW currently holds the highest overall quantitative score in the immediate peer group at 53/100 (D+) compared with SPTX at 48/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SPTX ACTIVE
Seaport Therapeutics Inc.
D 48/100 — — — +2.09% $1.05B Benchmark Subject
CTY
City Therapeutics Inc.
D 50/100 — — — +0.82% $1.04B /cty-vs-sptx →
HROW
Harrow Inc.
D+ 53/100 — 75.1% 42.9% -0.14% $1.06B /hrow-vs-sptx →
JANX
Janux Therapeutics Inc.
D- 37/100 — — -13.8% -0.06% $1.07B /janx-vs-sptx →
MLTX
MoonLake Immunotherapeutics (Class A)
E 32/100 — — -35.0% -2.63% $1.00B /mltx-vs-sptx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002042347 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Seaport Therapeutics Inc. (SPTX) reported GAAP revenue of $104.6M , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, SPTX closed FY2025 with $249.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $104.6M $0 — — $249.0M —

3. SPTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SPTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Seaport Therapeutics Inc. (NASDAQ: SPTX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $20.01 (+2.09% 1D, market cap $1.05B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, SPTX ranks #287 in composite RQD confidence.

How does SPTX compare to CTY and HROW in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SPTX carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CTY (City Therapeutics Inc.) holds a D grade (50/100 RQD, P/E N/A, ROIC —, cap $1.04B) and HROW (Harrow Inc.) posts a D+ grade (53/100 RQD, P/E N/A, ROIC 42.9%, cap $1.06B). Among the 5-stock peer group, SPTX leads on earnings multiple (N/A) while HROW leads on capital efficiency (42.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SPTX?

Per SPTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002042347), Seaport Therapeutics Inc. generated $104.6M in revenue, $0 in net income, and $0 in free cash flow against $249.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SPTX trading relative to its 50-day, 200-day, and 52-week technical levels?

SPTX last traded at $20.01 (+2.09% on volume of 527,909 shares), positioning the stock -4.76% below its 50-day simple moving average ($21.01) and -0.60% below its 200-day simple moving average ($20.13). Across its 52-week range of $14.85 to $28.38, SPTX sits at the 38.1% percentile with a 14-day RSI of 48.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($17.51 to $22.51).

Direct Sub-Reports: SPTX RQD Cockpit SPTX 12M Forecast SPTX Earnings & Move SPTX Dividends & DRIP SPTX Insiders & 13F SPTX Whale Options SPTX Profit Sankey SPTX News & Why
ROARABLE RATING BRIEF • RQD 48/100 (D) ✓ SEC XBRL & RQD VERIFIED

SPTX — Seaport Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Seaport Therapeutics Inc. (SPTX) earns a live Roarable RQD composite score of 48/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $20.01 (+2.09% 1D, market capitalization $1.05B).

  • Fundamental Cash Engine (10/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (7/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Seaport Therapeutics Inc. (SPTX) is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry..1B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Seaport Therapeutics Inc. (SPTX) reported $104.6M in annual revenue and $0 in GAAP net income. Operating cash flow reached $0 and free cash flow totaled $0, backed by $249.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 48/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 7/20. With Fundamental Cash Engine at 10/20 and Institutional Whale Flow at 7/20, sustained execution supports upside toward the upper end of the $14.85 – $28.38 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore — The only sector context provided is the Health Care / Biotechnology: Pharmaceutical Preparations classification and beta of 1.0. Investors should watch the lock-up expiry of 28-OCT-2026 as the nearest identifiable supply-of-shares event, since it may affect trading dynamics in the stock.

  • Key Question #1: Can SPTX sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $104.6M and free cash flow of $0, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is SPTX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SPTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Seaport Therapeutics Inc. (SPTX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SPTX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SPTX Bull vs. Bear Conversation Board — What's Your Call at $20.01?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SPTX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on SPTX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $23.72 (+21.0%)
📌 Pinned Debate

The stock trades near $21.10 with a balance sheet pillar scoring 13 / 20, supported by an Altman Z of 2.5 and Piotroski F of 6/9.

The stock trades near $21.10 with a balance sheet pillar scoring 13 / 20, supported by an Altman Z of 2.5 and Piotroski F of 6/9.. When you look under the hood at SPTX, Fundamental Cash Engine is 10/20 with 0.0% gross margins and 0.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (7/20) has been quietly accumulating below $28.38. My 12M target is $23.72.

VolSurface_Trader 🐂 BULL

@SkepticalCFA Shorting a 7/20 institutional whale-flow stock at $19.60 is dangerous when funds are rotating into Health Care.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $15.68 (-20.0%)
Spot @ $19.60

With ROIC at 0%, FCF yield at 0%, and insider conviction scoring 9 / 20, the reported data shows no cash generation or insider signalin

Fading this rally in SPTX at $19.60. With ROIC at 0%, FCF yield at 0%, and insider conviction scoring 9 / 20, the reported data shows no cash generation or insider signaling.. With a beta of 1.0 and the stock sitting at $19.60 (52-wk range $14.85–$28.38), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%